Biotech Analyst Biegler, along with Dr Krishnamurthy, Associate Professor of Medicine & Co-Director of Breast Cancer Program at the University of Nebraska Medical Center, discuss the rapidly changing treatment landscape (relevant companies ARVN, AZN, CELC, LLY, OKUR, OLMA) for HR-Positive Breast Cancer on an Analyst/Industry conference call to be held on March 18 at 10 am.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARVN:
- Biotech Alert: Searches spiking for these stocks today
- Arvinas price target lowered to $12 from $48 at Morgan Stanley
- Arvinas price target lowered to $32 from $57 at Guggenheim
- Buy Rating for Arvinas Holding Company Amid Promising VERITAC-2 Trial Results and Potential Market Edge
- Arvinas downgraded to Neutral from Buy at Goldman Sachs